Echo Therapeutics Announces Successful Unveiling of Symphony CGM System

Echo Therapeutics, Inc., a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, has announced the successful unveiling and demonstration of its Symphony CGM System during a live webcast following its annual stockholders meeting. Additionally, the Company's stockholders approved all resolutions proposed by Echo Therapeutics' Board of Directors during the meeting.

A replay of the corporate presentation and demonstration of the features and functionality of the Symphony CGM System is available at http://discovervideo.com/events/echo/20130522/..

"We are encouraged by the tremendously positive feedback we received from doctors, clinicians, and shareholders on Symphony's features and benefits that were demonstrated during the webcast. We believe that Symphony can improve glucose monitoring in hospitals and help alleviate the burden on both patients and caregivers," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "Additionally, we thank our shareholders for their participation in the proxy process and for supporting all of the Company's proposals."